Literature DB >> 27525839

Low miR-29c expression is a prognostic marker in hepatocellular carcinoma.

C W Dong1,2, Y X Wang2, F T Du2, W Ding2, S Y Hu1.   

Abstract

A previous study has revealed that miR-29c functions as a tumor suppressor in hepatocellular carcinoma (HCC), but the clinical significance and prognostic value of miR-29c in HCC have not been investigated. Paired human HCC tissues and adjacent noncancerous tissues were obtained from 91 patients, between 2008 to 2014. Quantitative real-time PCR (qRT-PCR) was used to analyze miR-29c expression. Kaplan-Meier survival plots and log-rank tests were used to assess differences in the overall survival of different subgroups of HCC patients. It was observed that miR-29c expression was remarkably decreased in HCC tissues relative to that in normal hepatic tissues (P < 0.001). The low miR-29c level was significantly associated with histologic grade (P = 0.001), microvascular invasion (P = 0.005), and tumor stage (P < 0.001). Kaplan-Meier analysis showed that decreased miR-29c expression correlated with shorter overall survival (P = 0.002). Multivariate Cox regression analysis showed that decreased miR-29c expression (hazard ratio = 2.19, 95%CI = 1.361-6.779, P = 0.025) was independently associated with poor survival in HCC. Our findings demonstrate that miR-29c expression is significantly downregulated in HCC patients and that miR-29c can act as an independent predictor of unfavorable clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27525839     DOI: 10.4238/gmr.15037316

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  4 in total

Review 1.  Recent advances in hepatocellular carcinoma therapy.

Authors:  Rinku Dutta; Ram I Mahato
Journal:  Pharmacol Ther       Date:  2017-02-05       Impact factor: 12.310

2.  Long non-coding RNA LINC00473 acts as a microRNA-29a-3p sponge to promote hepatocellular carcinoma development by activating Robo1-dependent PI3K/AKT/mTOR signaling pathway.

Authors:  Qiqin Song; Hongyue Zhang; Jinan He; Hongyan Kong; Ran Tao; Yu Huang; Haijing Yu; Zhongwei Zhang; Zhiyong Huang; Lai Wei; Chenghai Liu; Likui Wang; Qin Ning; Jiaquan Huang
Journal:  Ther Adv Med Oncol       Date:  2020-08-27       Impact factor: 8.168

3.  MicroRNA-29c restores cisplatin sensitivity in liver cancer through direct inhibition of sirtuin 1 expression.

Authors:  Wei Zhang; Peng Luo
Journal:  Oncol Lett       Date:  2018-05-24       Impact factor: 2.967

4.  Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis.

Authors:  Yue Zhang; Chao Wei; Cong-Cong Guo; Rong-Xiu Bi; Jin Xie; Dong-Hui Guan; Chuan-Hua Yang; Yue-Hua Jiang
Journal:  Oncotarget       Date:  2017-09-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.